

Technology Opportunity Bulletin

Prognostic Tool for Chronic Heart Failure (CHF)

Tech ID: 2007-044

Description:

We have developed a novel ECG technology that predicts mortality with great accuracy, within 5 years, in chronic heart failure patients. Currently there are no reliable or accurate tests to predict CHF mortality.

In a proof-of-concept study, our technology was successful in predicting, with almost 100% sensitivity and 80% specificity, death of ambulatory CHF patients within 5 years. In contrast, in this same patient population, multivariate analyses using existing clinical prognostic variables was substantially less effective at predicting death within 5 years. Larger prospective validation studies are currently under way in a different CHF population treated with beta-blocking drugs.

Applications:

1. Decision on patient inclusion and/or patient stratification for clinical trials in heart failure.
2. Monitoring and alter treatment regimens to increase efficacy and improve survival benefit of CHF patients.
3. Help make go/no-go decision for physicians on whether to implant an ICD in CHF patients. This is a \$6 billion (USD) market and companies are eager for new competitive advantages.

Status of Development:

This technology is currently being validated in a prospective 352 CHF patient population. A U.S. provisional patent application has been submitted.

Status of Commercialization:

PARTEQ Innovations, the technology transfer company of Queen's University, is seeking industrial partners willing to support ongoing development of the product and/or who are interested in licensing the intellectual property.

Contact:

Mike Wells Ph.D., MBA
Manager, Commercial Development in Life Sciences
Phone: (613) 533-2342
FAX: (613) 533-6853
E-mail: mwells@parteqinnovations.com